Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 5, 2008, Pages 746-751

  Miyamoto, Masaki ^a   Haruma, Ken ^b   Takeuchi, Keisuke ^a   Kuwabara, Masao ^a  

^a Hiroshima Prefecture Hiroshima Hospital   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Frequency scale for the symptoms of GERD (FSSG) questionnaire; Gastroesophageal reflux disease; Prokinetics; Proton pump inhibitor therapy

Indexed keywords

MOSAPRIDE CITRATE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CHRONICITY; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SYMPTOMATOLOGY;

EID: 42049120978     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05218.x     Document Type: Article

References (23)

1. Kusano M, Shimoyama Y, Sugimoto S et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J. Gastroenterol. 2004 39 : 888 91.
2. Kusano M, Shimoyama Y, Kawamura O et al. Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients. Dig. Dis. Sci. 2007 52 : 1673 7.
3. Armstrong D, Dent J, Bennett JR et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996 111 : 85 92.
4. Hoshihara Y. Reflux esophagitis. In : Nagasako K, Fujimori T, Hoshihara Y, Tabuchi M, eds. Atlas of Gastroenterologic Endoscopy by High-Resolution Video-Endoscope. Tokyo : Igaku-Shoin, 1998 32.
5. Yoshida N, Kato S, Ito T. Mosapride citrate. Drug Future 1993 18 : 513 5.
6. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal disease. Scand. J. Gastroenterol. 1993 28 (Suppl. 199 18 21.
7. Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastro-oesophageal reflux disease in general practice. BMJ 2001 322 : 344 7.
8. Quigley EM. Review article: gastric emptying in functional gastrointestinal disorders. Aliment Pharmacol. Ther. 2004 20 (Suppl. 7 56 60.
9. Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N. Engl. J. Med. 1995 333 : 1106 10.
10. Ruth M, Finizia C, Cange L, Lundell L. The effect of mosapride on oesophageal motor function in patients with gastro-oesophageal reflux. Eur. J. Gastroenterol. Hepatol. 2003 15 : 1115 21.
11. Ruth M, Hamelin B, Rohss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol. Ther. 1998 12 : 35 40.
12. Madan K, Ahuja V, Kashyap PC, Sharma MP. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis. Esophagus. 2004 17 : 274 8.
13. Carlsson R, Dent J, Bolling-Stenevald E et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand. J. Gastronterol. 1998 33 : 1023 9.
14. Svedlund J, Sjodin I, Dotevall G. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcers. Dig. Dis. Sci. 1998 33 : 129 34.
15. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36). Med. Care. 1992 30 : 473 81.
16. Stanghellini V, Armstrong D, Monnikes H, Bardhan KD. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol. Ther. 2004 19 : 463 79.
17. Lin M, Gerson LB, Lascar R, Davila M, Triadafilopoulos G. Features of gastroesophageal reflux disease in women. Am. J. Gastroenterol. 2004 99 : 1442 7.
18. Saitoh T, Fukushima Y, Otsuka H et al. Effect of rabeprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol. Ther. 2002 16 : 1811 7.
19. Thjodleifsson B, Rindi G, Fiocca R. et al. A randomized, double-blind trial of efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol. Ther. 2003 17 : 343 51.
20. Haruma K, Kamada T, Kawaguchi H et al. Effect of age and Helicobacter pylori infection on gastric acid secretion. J. Gastroenterol. Hepatol. 2000 15 : 277 83.
21. Feldman M, Richardson CT, Lam SK, Samloff IM. Comparison of gastric acid secretion rates and serum pepsinogen I and II concentrations in Occidental and Oriental duodenal ulcer patients. Gastroenterology 1988 95 : 630 5.
22. El-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995 109 : 681 91.
23. Takeuchi Y, Watanabe H, Imawari M. Mosapride citrate, a serotonin 5-HT4 selective agonist, beneficially affects pharmacokinetics of proton pump inhibitor. Gastroenterology 2005 4 (Suppl. 2 A531.